Coherus Oncology (CHRS) FCF Margin Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) FCF Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5,426.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9,545.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4,612.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1,850.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 14,060.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -3,088.00 |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -36,754.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36,754.00 |
| Mar 31, 2026 | -25,787.00 |
| Dec 31, 2025 | 22.00 |
| Sep 30, 2025 | -31,782.00 |
| Jun 30, 2025 | 434,414.00 |
| Mar 31, 2025 | -31,104.00 |
| Dec 31, 2024 | 44,192.00 |
| Sep 30, 2024 | -104,102.00 |
| Jun 30, 2024 | 96,936.00 |
| Mar 31, 2024 | 611,018.00 |
| Dec 31, 2023 | -4,331.00 |
| Sep 30, 2023 | -11,266.00 |
| Jun 30, 2023 | -10,905.00 |
| Mar 31, 2023 | -22,243.00 |
| Dec 31, 2022 | -23,382.00 |
| Sep 30, 2022 | -13,187.00 |
| Jun 30, 2022 | -9,962.00 |
| Mar 31, 2022 | 6,358.00 |
| Jun 30, 2020 | 408,082.00 |
| Mar 31, 2020 | 4.66 Mn |